We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Fosrenol Brochure Omits Risks, Overstates Efficacy
Shire Development has been told by the FDA to stop disseminating a promotional brochure for Fosrenol chewable tablets because the pamphlet misleads patients
about the risks and benefits of the drug.